TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06989840: Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne

Sponsor: Sagimet Biosciences Inc. · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 152 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$2,280,720

Rescue Site Savings

+$1,508,784

Unlock Full NCT06989840 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06989840 Rescue Dossier →